Type 3 Lesions Raise Macular Atrophy Risk in Wet AMD
The authors said Type 3 lesions, subretinal drusenoid deposits and thinner choroids may help identify patients at higher risk and inform monitoring. Photo: Mohammad Rafieetary, OD. Click image to enlarge. For people treated for neovascular age-related macular degeneration (nAMD), the type of lesion may help identify who is more likely to develop macular atrophy, a complication that can contribute to vision loss. In a study published in Acta Ophthalmologica , researchers in France examined atrophy occurrence and progression across macular neovascularization (MNV) subtypes. The retrospective study included 416 treatment-naive eyes from 340 patients at six retina centers. All eyes received anti-VEGF treatment and were followed for a mean of about 4.5 years. By the end of follow-up, 197 eyes (47.4%) had macular atrophy. That total included 79 eyes with atrophy at the start of the study; 118 developed it during follow-up. At the end of follow-up, atrophy was present in 82% of eyes with Type 3 MNV, compared with 34% of eyes with Type 1 MNV and 45% of eyes with a subretinal component (Type 2 or mixed Type 1 and 2). The 82% figure includes eyes that already had atrophy at diagnosis. An analysis of eyes without atrophy at the start of the study also found a higher likelihood of developing it in those with Type 3 lesions. In adjusted analyses, Type 3 MNV, subretinal drusenoid deposits and thinner choroids were independently associated with higher risk of developing atrophy. A greater proportion of visits with subretinal fluid was associated with lower risk. This association does not establish that fluid protects against atrophy. Atrophy enlargement averaged 1.0 mm2 per year overall. It was fastest in eyes with a subretinal component, at 1.5 mm2 per year, compared with 0.9 mm2 per year for Type 1 and Type 3 lesions. The difference was not statistically significant when the researchers used a square-root-transformed measure of lesion size. The cumulative number of anti-VEGF injections was not independently associated with atrophy after adjustment. The authors cautioned that this does not show treatment intensity has no effect: injection frequency can reflect disease activity, lesion subtype and follow-up patterns. “This finding should not be interpreted as evidence that treatment intensity has no effect on macular atrophy development,” they wrote. Because the study was retrospective, and treatment and follow-up varied, its findings cannot establish cause and effect. The authors said recognizing higher-risk features may help clinicians assess prognosis and plan follow-up while continuing to treat active neovascular disease. Click here for the journal source. Moulin A, Zeender G, Rizzuto P, et al. Occurrence, progression and risk factors of macular atrophy in neovascular age-related macular degeneration according to neovascularization subtypes. Acta Ophthalmologica. November 5, 2026. [Epub ahead of print.] This article was developed by the editorial staff in conjunction with experts in the field. In the process, AI may have been among the editorial tools used to meet the goals of human editors, who approved all content.